Antibodies directed against TNF-α and IL-6 have shown efficacy for the treatment of RA, consistent with the fact that joint destruction is positively correlated with pro-inflammatory cytokine levels in the serum or synovial tissue. This evidence concerns the gene IL6 and rheumatoid arthritis.